In a recent pivotal study by Hinohara and colleagues, the epigenetic enzyme, KDM5B, was found to be a regulator of transcriptomic heterogeneity in a panel of ER + breast cancer cell lines, promoting resistance to endocrine therapy. Here, ESR1 is linked to breast cancer.